Subscribe To
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an […] The post Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023 appeared first on ForexTV...
Read More
Posted: Oct 15 2023, 22:07
Author Name: forextv
Views: 110843